ALK and non-small cell lung carcinoma: Despite its efficacy, a substantial proportion of patients relapse after drug withdrawal.405 Furthermore, some optimized ALK degraders exhibited efficacy in NSCLC,406,407 which may provide an alternative therapy for drug-resistant and R/R patients and resolve the conundrum of discontinuation.